Country sequencing, vendor geography, and QP release chains are strategic decisions made, well or poorly, at the US IND stage, long before a company believes it is ready to think globally.
White Paper
Designing a Global IND Strategy Before You Think You Need One
Related Resources
All Resources
post
Writing a Complex IND: The Top 3 Challenges and How to Avoid Them
Read More
post
Performing CMC Due Diligence for Molecule Licensing and Acquisitions
Read More
post
Why Protocol Amendments Matter: A Clinical Regulatory Medical Writing Perspective
Read More
post
Understanding FDA’s Real-Time Oncology Review (RTOR Medical Abbreviation) Program
Read More
Let's move from science to success.
Let’s Talk